Article Text

PDF
Population-based p16 and HPV positivity rates in oropharyngeal cancer in Southeast Scotland
  1. L A R Wells1,
  2. E J Junor1,
  3. B Conn2,
  4. S Pattle3,
  5. K Cuschieri3
  1. 1Department of Oncology, Western General Hospital, Edinburgh, UK
  2. 2Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK
  3. 3Scottish Reference HPV Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK
  1. Correspondence to Dr Lucy Wells, Department of Oncology, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK; Lucy.wells{at}luht.scot.nhs.uk

Abstract

We assessed a population-based cohort of patients diagnosed with oropharyngeal squamous cell carcinoma in Southeast Scotland over 13 months. p16 and human papilloma virus (HPV) expression were determined, and correlated with stage, treatment, smoking and alcohol history, and disease outcomes. Retrospective analysis was performed on 60 patients. p16 immunohistochemistry and HPV genotyping were performed on formalin-fixed paraffin-embedded tissues. HPV infection (as defined by p16 positivity and/or HPV PCR positivity) was identified in 57% of samples, while dual positives were detected in 45% of cases. HPV16 was most prevalent of the HPV types and was associated with 90% of positive samples. Cause-specific 1-year and 2-year survivals were 82.5% and 78.2%, respectively. The p16-positive and HPV-positive groups demonstrated significantly increased cause-specific survival in comparison with their negative counterparts.

  • HEAD AND NECK CANCER
  • HPV
  • PAPILLOMA VIRUSES
  • IMMUNOHISTOCHEMISTRY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.